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Abstract

β
-adrenergic receptor blockers (β-blockers) are commonly used to treat heart failure, but the biological mechanisms governing their efficacy are still poorly understood. The complexity of β -adrenergic signaling coupled with the influence of receptor polymorphisms makes it difficult to intuit the effect of β -blockers on cardiac physiology. While some studies indicate that β -blockers are efficacious by inhibiting β -adrenergic signaling, other studies suggest that they work by maintaining β -adrenergic responsiveness. Here we use a systems pharmacology approach to test the hypothesis that in ventricular myocytes, these two apparently conflicting mechanisms for β -blocker efficacy can occur concurrently. We extended a computational model of the β 1 -adrenergic pathway and excitation-contraction coupling to include detailed receptor interactions for 19 ligands. Model predictions, validated with Ca 2+ and FRET imaging of adult rat ventricular myocytes, surprisingly suggest that β -blockers can both inhibit and maintain signaling depending on the magnitude of receptor stimulation. The balance of inhibition and maintenance of β 1 -adrenergic signaling is predicted to depend on the specific β -blocker (with greater responsiveness for metoprolol than carvedilol) and β 1 -adrenergic receptor Arg389Gly polymorphisms.
Introduction β -adrenergic receptor blockers (β-blockers) are front-line therapies for the treatment of heart failure, yet the biological mechanism governing their success is still poorly understood (El-Armouche and Eschenhagen, 2009; Krum, 2003; Tilley and Rockman, 2006) . The β 1 -adrenergic receptor pathway has a dominant role in the regulation of heart contractility (Saucerman and McCulloch, 2006) . One of the hallmarks of heart failure is elevated catecholamine release, which desensitizes the β -adrenergic pathway causing an inability to increase contractility and cardiac output in response to acute stress (Ungerer et al., 1994) . Two apparently conflicting theories commonly postulated are that β -blockers are effective in heart failure by either inhibiting the harmful consequences of sustained adrenergic stimulation or maintaining the beneficial aspects of β 1 -adrenergic receptor pathway activation (Lohse et al., 2003) . The inhibition hypothesis is supported by clinical and experimental evidence that β -blockers help prevent or reverse the cardiac remodeling that leads to heart failure (Lowes et al., 1999) . Conversely, the maintenance hypothesis is given credence by clinical evidence that β -blockers increase β 1 -adrenergic receptor levels (Michel et al., 1988) and exercise tolerance (Engelmeier et al., 1985) .
The ability of different β -blockers to either inhibit or maintain signaling is varied, causing controversy about which β -blocker is more effective in heart failure (Metra et al., 2006) . Among the 17 FDA approved β -blockers, a variety of pharmacological properties beyond receptor specificity alone may contribute to these differences (Mason et al., 2009) . For example some β -blockers are inverse agonists (Metra et al., 2006) , reducing signaling below basal levels (Parra and Bond, 2007) . Yet the importance of inverse agonism in determing clinical outcome during β -blocker treatment is unclear.
Genetic differences among patients also impacts β -blocker efficacy (Krum, 2003) . In vitro experiments in cell expression systems show that the common β 1 AR-Arg389Gly single-nucleotide polymorphism has a higher fold increase in adenylyl cyclase activity after receptor stimulation but is more desensitized (Mason et al., 1999; Rathz et al., 2003) . Carvedilol and metoprolol have similar affinity for both receptor variants in vitro (Joseph et al., 2004) , but carvedilol has a larger effect on receptor This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Computational model of β -blockers and β -adrenergic signaling A computational model was previously developed that integrates β 1 -adrenergic receptor signaling with excitation contraction coupling in rat cardiac myocytes and is based on mass action kinetics (Saucerman et al., 2003) . The receptor module was previously described by a ternary complex model (De Lean et al., 1980) . To better model the inverse agonism of some β -blockers seen in in vitro experiments (Varma et al., 1999) , the receptor module of our original β 1 -adrenergic receptor signaling model was replaced with the extended ternary complex model (ETCM) (Samama et al., 1993) . The ETCM (Figure 1) proposes two receptor states i.e. active and inactive and appropriately describes the constitutive activity of This article has not been copyedited and formatted. The final version may differ from this version. 
Average fluo-4 fold change was calculated by averaging 5-7 consecutive transients at specific time points. All segmentation and feature extraction was implemented in MATLAB. Code for these analyses and example movies are freely available at http://bme.virginia.edu/saucerman.
FRET imaging of cardiac myocytes
This article has not been copyedited and formatted. The final version may differ from this version. Adenovirus was constructed from plasmid DNA of AKAR3 protein kinase-A reporter (Allen and Zhang, 2006) . Myocytes were infected with adenovirus immediately following isolation in serum MEM media for 1 hour. Cells were then cultured for 24 hours in serum free MEM media. Myocytes were preincubated in solutions of 0.1 µM isoproterenol with and without 0.1 µM propranolol. Cells were placed in a slotted bath with Tyrodes perfusate and paced at 10 Hz. Expressing myocytes were imaged on an Olympus IX-81 inverted microscope with a Hamamatsu C9300 CCD camera. A cocktail of 10 μ M forskolin (FSK; Tocris, Minneapolis, MN) and 100
Louis, MO) was used as positive control at the end of each experiment. Automated cell segmentation and FRET computation (using PFRET algorithm (Chen and Periasamy, 2006) ) were performed in MATLAB.
FRET response was normalized to positive control. transients at 0.1 µM isoproterenol (Supplemental Figure 3) . Low and high doses of isoproterenol are analogous to chronically elevated levels of catecholamines in HF and acutely elevated levels in exercise, respectively. In the absence of propranolol, the model predicts that low receptor stimulation increases Ca 2+ amplitude ( Figure 3A) , with no further sensitivity to subsequent high levels of isoproterenol ( Figure   3B ). In the presence of propranolol, responsiveness to low receptor stimulation is suppressed but the pathway maintains sensitivity of Ca 2+ transients to high isoproterenol ( Figure 3C ). Independent experiments imaging Ca 2+ dynamics in isolated adult rat ventricular myocytes qualitatively validated these model predictions ( Figure 3D , E, and F). These simulations and experiments indicate that the MOL #90951
Results
Calibration and validation of
1 0 apparently conflicting roles of the β -blocker propranolol to inhibit signaling and maintain responsiveness are in fact compatible.
To experimentally investigate whether these effects persist with chronic receptor stimulation, cells were pre-treated with a low dose of isoproterenol for 24 hours before subsequent stimulation with high isoproterenol (Figure 4 ). In the absence of propranolol, Ca 2+ transient amplitude in pre-treated cells was not further sensitive to high isoproterenol ( Figure 4C ), as Ca 2+ transients were already elevated. In contrast, cells pre-treated with propranolol maintained sensitivity to high dose of isoproterenol in the presence of propranolol, similar to model predictions and the acute experiments (Figure 3 ). Using a FRET reporter for PKA activity, we found that PKA (upstream of Ca 2+ in the β 1 -adrenergic pathway) also maintains sensitivity to high isoproterenol in the presence of propranolol ( Figure 4B ), again validating model predictions (Supplemental Figure 8 ).
β -blockers differ in their ability to inhibit and maintain β -adrenergic responsiveness
To examine whether the dual role of propranolol in inhibiting and maintaining β -adrenergic responsiveness may be generalized to other β -blockers, we extended the model to 17 additional β -adrenergic receptor ligands. Two key ligand specific properties, ligand dissociation constant (K L or K A ) and inverse agonism (α L or α A ), were calibrated using data on ligand binding and adenylyl cyclase activity for these 19 ligands in CHO cells overexpressing human β 1 -adrenergic receptor (Hoffmann et al., 2004) (Supplemental Figure 2) .
We then performed an in silico screen of the 19 ligands for effects on β -adrenergic responsiveness ( Figure 5 ). Similar to simulations in Figure 3 , low and then high isoproterenol were simulated in the presence and absence of the indicated ligand at 1 µM. The model predicted substantial diversity in the ability of ligands to maintain cAMP sensitivity to subsequent high dose isoproterenol ( Figure 5A ). To understand this diversity, we examined correlations between cAMP sensitivity and the ligand specific parameters K L and α . As shown in Figure 5B , ligand binding affinity was predicted to influence cAMP sensitivity in a biphasic manner (e.g. metoprolol had the highest cAMP sensitivity with a 1 1 moderate K L ). In order for the initial binding event to occur, a β -blocker needs to have a low enough binding affinity to compete out the receptor agonist. There is also a modest positive correlation between α and cAMP sensitivity, suggesting that ligands with high α (indicating a high degree of inverse agonism) preferentially increase cAMP sensitivity ( Figure 5B ). This is due to such ligands keeping the receptor in an inactive state, preventing receptor desensitization (Supplemental Figures 8-10 ). Neither ligand binding affinity nor inverse agonism is sufficient alone to predict cAMP sensitivity. Thus the ability of β -blockers like metoprolol to maintain cAMP sensitivity was due to both inverse agonism and binding affinity.
Metoprolol and carvedilol differ in their ability to maintain β -adrenergic responsiveness
An interesting prediction of the in silico screen is that carvedilol and metoprolol (two clinically prescribed β -blockers) differ significantly in their ability to enhance cAMP sensitivity. This difference
indicates that the two drugs may have distinct effects (inhibition or maintenance) on the β 1 -adrenergic response. To experimentally validate model predictions for carvedilol and metoprolol, Ca 2+ imaging experiments in adult rat ventricular myocytes were performed. As with propranolol, we empirically selected doses for carvedilol and metoprolol that were just sufficient to suppress response to 0.1 µM isoproterenol (Supplemental Figure 4) . Sensitivity to high isoproterenol was maintained in cardiac myocytes treated with 1 µM metoprolol ( Figure 6A ) but suppressed with 1 µM carvedilol ( Figure 6B ), qualitatively validating our model predictions (summarized in Figure 6C and D),
To test the robustness of this result to β -blocker concentration, we further simulated how cAMP sensitivity is affected by propranolol, metoprolol and carvedilol doses. The model predicted that propranolol and metoprolol robustly maintained β -adrenergic responsiveness, but that at doses lower than we had previously examined, carvedilol may also maintain β -adrenergic responsiveness (Supplemental Figure 5 ). To test this prediction, we performed subsequent experiments with 0.3 µM carvedilol (Supplemental Figure 6 ), which showed that lower carvedilol still suppressed the responsiveness to high isoproterenol. The robust suppression seen in the carvedilol experiments can be explained by an alternative receptor model accounting for binding of carvedilol to an allosteric site on the β 1 -adrenergic MOL #90951
1 2 receptor (Supplemental Figure 7) , as supported by previous experiments by Kindermann et al. (Kindermann et al., 2004) .
Receptor polymorphisms are differentially modulated by diverse β -blockers
Genetic differences among patients also impacts β -blocker efficacy (Shin and Johnson, 2010 Figure 7A ) and the higher constitutive activity of the Arg389 variant ( Figure 7B ). β 1 -Arg389 and β 1 -Gly389 polymorphisms were predicted to have varying responses to PRO. Propranolol had more of an effect inhibiting the low isoproterenol cAMP and Ca 2+ response in the Arg389 variant ( Figure 7C ) but also enhanced sensitivity to high isoproterenol. The 19 ligands were predicted to have varying effect on cAMP sensitivity ( Figure 7D ), similar to the β 1 -Gly389 variant ( Figure 5A ). However, there are some significant differences in the response to particular ligands between the receptor polymorphisms ( Figure   7E ). For example, atenolol was predicted to be less effective at maintaining β -adrenergic responsiveness for the β 1 -Arg389 variant compared with the β 1 -Gly389 variant. This diversity of responses indicates that computational models may be useful for predicting pharmacogenetic interactions.
Discussion
Mechanisms of β -blocker efficacy in heart failure
A key feature of heart failure (HF) is the modest chronic elevation of circulating catecholamines (e.g. epinephrine) which desensitizes the β -adrenergic receptor signaling pathway, rendering patients MOL #90951
1 3 incapable of increasing cardiac output in response to intense acute stress (e.g. exercise). Crucial alterations to the signaling pathway in this chronically activated state include reduced β 1 -adrenergic receptor density (Bristow et al., 1982) and Ca 2+ (Harding et al., 1992) in response to adrenergic stimulation. Sustained stimulation has detrimental long term consequences including apoptosis and hypertrophy (Communal et al., 1998; Taimor et al., 2001 (Lowes et al., 1999) or maintenance of β 1 -adrenergic receptor signaling (Engelmeier et al., 1985; Michel et al., 1988) . With evidence supporting both theories, it is unclear how these two contradictory mechanisms can explain the same biological phenomena or the appropriate context where one mechanism dominates. This study provides evidence that at least in normal isolated adult ventricular myocytes, both mechanisms can occur concurrently dependent on the magnitude of receptor stimulation.
Complexities at the receptor level and the influence of receptor polymorphisms complicate attempts to infer these mechanisms. Computational modeling is highly suited for this task by allowing the unbiased comparison of clinically available β -blockers. Previous computational models of the β 1 -adrenergic receptor pathway have used simplified receptor kinetic models (Saucerman et al., 2003 (Saucerman et al., , 2004 .
Although sufficient to describe the activation of the signaling pathway by agonists, these pathway models do not have the mechanistic detail of receptor kinetics needed to adequately model the inverse agonism of β -blockers. Detailed receptor models have been developed but these models have been evaluated in isolation from downstream signaling pathways (Samama et al., 1993 and FRET imaging of isolated cardiac myocytes confirmed this prediction.
Metoprolol and carvedilol have distinct mechanisms of action in isolated ventricular myocytes
Separate clinical trials of the two β -blockers commonly used to treat heart failure show reduction in mortality. Results of the COMET trial, which aimed to compare both treatments, concluded that carvedilol had a larger effect on mortality (Poole-Wilson et al., 2003) . Significant controversy surrounds this result with questions raised on the appropriate dose of each compound that merits fair comparison (Kveiborg et al., 2007) . Another important clinical measure of heart failure treatment effectiveness is exercise tolerance. Studies have shown that metoprolol has a larger effect on exercise tolerance versus carvedilol (Metra et al., 2000) . Our computer simulations and Ca 2+ imaging experiments confirm that metoprolol maintains β -adrenergic signaling in isolated ventricular myocytes due to its moderate binding affinity and high inverse agonism. Carvedilol, although also an inverse agonist, did not maintain isoproterenol sensitivity due to its tight binding to the β 1 -adrenergic receptor and potential contribution from allosteric binding (Kindermann et al., 2004) .
Pharmacogenomic targeted treatment with β -blockers
Another factor complicating treatment of heart failure patients is the presence of β -adrenergic receptor polymorphisms. β 1 -Gly389 has been show to couple less effectively to G-protein in expression cell systems but the β 1 -Arg389 variant provides higher risk to heart failure and differential response to β -blockers. A recent study has shown that carvedilol exhibits enhanced inverse agonism with the β 1 -Arg389 is not yet able to fully explore the consequence of this mechanism in vivo. Future work could couple the β 1 -adrenergic signaling model to whole-body pharmacokinetics or simulate crosstalk with other adrenergic receptors including the β 2 -adrenergic receptor (Zamah et al., 2002) .
Conclusions
Previous studies have suggested two seemingly conflicting mechanisms (inhibition or maintenance of the β -adrenergic receptor signaling pathway) to explain β -blocker efficacy. Here we show both in pathway models and adult ventricular myocytes that the β -blockers propranolol and metoprolol (but not carvedilol) not only block response to low isoproterenol (analogous to chronic stimulation in HF)
but maintain the β -adrenergic receptor response to subsequent high isoproterenol (analogous to acute stimulation in exercise). Thus both inhibition and maintenance of signaling can occur concurrently Ungerer, M., Parruti, G., Bohm, M., Puzicha, M., DeBlasi, A., Erdmann, E., and Lohse, M. (1994) . Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res 74, 206-213. Varma, D.R., Shen, H., Deng, X.F., Peri, K.G., Chemtob, S., and Mulay, S. (1999 (Mason et al., 1999) , (Vila Petroff et al., 2001) , (De Arcangelis et al., 2010) , (Vittone et al., 1998) and (Collins and Rodrigo, 2010) whereas data in D & F was acquired in the current study. 
